A new political action group taking on high drug prices has big plans in the works leading up to November’s midterm elections — and a seven-figure budget to make it happen.

David Mitchell, a cancer patient and the former head of a Washington, D.C., public policy firm, last week unveiled the new organization, called Patients for Affordable Drugs NOW. It’s a separate legal entity operating as the political arm of the advocacy group Patients for Affordable Drugs that Mitchell founded last year. Initial funding comes from an entity financed by the billionaire couple John and Laura Arnold, who’ve spent millions backing other research and advocacy on drug pricing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a cancer patient my drug last year started at $8000. Yes $8000. Now it is $11000.
    I know someone who worked for Bch/bs and the trips bonuses are what is driving our costs up. I’m with you

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy